

2024 US Hospital Tumor Marker Forecasts for Major Tests: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation Review

<https://marketpublishers.com/r/285C64EA3300EN.html>

Date: August 2024

Pages: 0

Price: US\$ 4,500.00 (Single User License)

ID: 285C64EA3300EN

Abstracts

This new report from LeadingMarketResearch.com contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including: Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next 5 years. ;Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others. ;Test volume and sales forecasts for 40 tumor markers performed in US hospitals.;Current instrumentation technologies and feature comparison of leading analyzers.;Sales and market shares of leading suppliers. ;Emerging diagnostic technologies and their potential market applications. ;Product development opportunities. ;Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. ;Business opportunities and strategic recommendations for suppliers.Contains 567 pages and 50 tables

Contents

Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology

1. BREAST CANCER

2. LUNG CANCER

3. COLON AND RECTUM CANCER

4. PROSTATE CANCER

5. STOMACH CANCER

6. LEUKEMIA

7. LYMPHOMA

8. ORAL CANCER

9. SKIN CANCER

10. UTERINE CANCER

11. OVARIAN CANCER

12. BLADDER CANCER

B. Major Current And Emerging Cancer Diagnostic Tests

1. INTRODUCTION

2. TUMOR MARKER CLASSIFICATION

3. ACTH

- 4. ALPHA-FETOPROTEIN (AFP)**
- 5. BETA-2 MICROGLOBULIN**
- 6. CA 15-3/27.29**
- 7. CA 19-9**
- 8. CA-125**
- 9. CALCITONIN**
- 10. CARCINOEMBRIONIC ANTIGEN (CEA)**
- 11. ESTROGEN AND PROGESTERONE RECEPTORS**
- 12. FERRITIN**
- 13. GASTRIN**
- 14. HUMAN CHORIONIC GONADOTROPIN (HCG)**
- 15. INSULIN**
- 16. NSE**
- 17. OCCULT BLOOD**
- 18. PAP SMEAR/HPV**
- 19. PROSTATIC ACID PHOSPHATASE (PAP)**
- 20. PROSTATE-SPECIFIC ANTIGEN (PSA)**
- 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)**
- 22. T AND B LYMPHOCYTES**

23. TDT

24. THYROGLOBULIN

25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL TUMOR MARKERS

- ADA
- B-Protein
- PNP
- 5'-Nucleotidase

27. ONCOGENES

- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src

I would like to order

Product name: 2024 US Hospital Tumor Marker Forecasts for Major Tests: Supplier Shares by Test, Competitive Landscape, Innovative Technologies, Instrumentation Review

Product link: <https://marketpublishers.com/r/285C64EA3300EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/285C64EA3300EN.html>